Company / Cash & Equivalents
BioMarin Pharmaceutical Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.3B
FY2025
5-year range
$587.3M / $1.3B
FY2021-FY2025
Trend
+39.1%
vs FY2024
Sector context
#17 of 207
Health Care
What the data says
Among 207 Health Care companies, BioMarin Pharmaceutical is in the top 8% for cash & equivalents. Cash & Equivalents has increased for 4 consecutive years, from $587M in FY2021 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +15.1%. Top quartile in the Health Care sector.
Improved from $755M to $1.3B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +21.9%
- 5-Year CAGR
- +15.1%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 207This company $1.3B Sector average $669.5M
▼
+95.9% above sector average
Key checks
Key Insights
- BioMarin Pharmaceutical's cash & equivalents has grown for 4 consecutive years.
- 5-year CAGR of +15.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 39.1% year-over-year.
- Ranks #17 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +39.1% |
| FY2024 | $942.8M | +24.9% |
| FY2023 | $755.1M | +4.2% |
| FY2022 | $724.5M | +23.4% |
| FY2021 | $587.3M | -9.5% |
| FY2020 | $649.2M | +48.4% |
| FY2019 | $437.4M | -11.4% |
| FY2018 | $494.0M | -17.4% |
| FY2017 | $598.0M | +46.5% |
| FY2016 | $408.3M | +2.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026